Tenderwize
Zurück zur Suche

Open-house rebate agreement for epinephrine prefilled syringe/prefilled pen

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Sep 30, 2026 · 35 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Epinephrin (ATC-Code nach WHO: C01CA24) in der Darr. Fertigspritze/Fertigpen

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

Participation documents must be submitted via the DTVP communication function, but the notice says some portal instruct...

Only pharmaceutical companies within the meaning of § 4(18) AMG may participate for the offered medicinal products, and...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2026
  • Non-exclusive rebate agreements for epinephrine medicinal products in prefilled syringe/prefilled pen form, excluding 500 micrograms.
  • Open-House participation model with contracts available to all interested eligible pharmaceutical companies during the participation period.
Vollständige Zusammenfassung anzeigen

This is an Open-House supply arrangement for non-exclusive pharmaceutical rebate agreements under §130a(8) SGB V for epinephrine (ATC C01CA24) in prefilled syringe/prefilled pen form, excluding 500 micrograms. The lead buyer is AOK PLUS. Participation is open to all eligible pharmaceutical companies during the participation period, with no individual negotiations and no supply exclusivity. Submission is electronic via DTVP communication functions, but the notice says some portal instructions are technically misleading and the participation documents must be obtained from the project room. No contract value is stated.

Risiken

Participation documents must be submitted via the DTVP communication function, but the notice says some portal instruct...

Only pharmaceutical companies within the meaning of § 4(18) AMG may participate for the offered medicinal products, and...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal products.
  • The company must accept the participation requirements and the rebate agreement terms.

Administrative

  • An application for access to the project room is required before downloading the participation documents.

Auftraggeber

Ort

Erfurt, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE256878834

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreement for epinephrine prefilled syringe/prefilled pen

Single lot covering non-exclusive rebate agreements for medicinal products with epinephrine (ATC C01CA24) in prefilled syringe/prefilled pen presentation, excluding 500 micrograms. The arrangement is an Open-House model with no exclusivity and no individual negotiations. Place of performance is Dresden, Germany, with performance geography stated as Germany, Saxony and Thuringia in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Ort

Dresden, Germany

Dauer

Sep 2025 - Sep 2026

Kategorie

Pharmaceutical products

Frist

Deadline Sep 30, 2026

Vergabedetails

Veröffentlichungsdatum
31 Jul 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
504736-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3